Baloxavir Marboxil
Brand names: Xofluza
Baloxavir marboxil is an oral antiviral of the cap-dependent endonuclease inhibitor class used for the treatment of uncomplicated influenza A and B in patients who present early.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Its active metabolite inhibits the cap-dependent endonuclease activity of the viral polymerase acidic protein, blocking initiation of viral mRNA synthesis and so halting influenza replication.
Prescribing in practice
- Effectiveness depends on starting treatment within the first couple of days of symptom onset, so confirm the timing of illness before prescribing.
- Polyvalent cations (such as antacids, oral calcium, magnesium, iron or some supplements) reduce absorption and should be separated in time from the dose.
- Treatment-emergent reduced-susceptibility variants can arise, which is most relevant in immunocompromised or paediatric patients.
Monitoring
Routine laboratory monitoring is not required; review clinically for symptom resolution and watch for rare hypersensitivity reactions.
Counselling the patient
- This medicine works best when taken as early as possible after flu symptoms begin.
- Avoid taking it at the same time as antacids, dairy products or mineral supplements.
- Seek advice if you develop a rash, facial swelling or difficulty breathing.
Evidence & guidelines
Single-dose efficacy in acute uncomplicated influenza was demonstrated in the CAPSTONE randomised controlled trials.
Reference: Hayden et al. NEJM 2018 (CAPSTONE-1); Ison et al. NEJM 2020 (CAPSTONE-2); MHRA SPC Xofluza; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis